Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Apr;28(2):203-9.
doi: 10.1097/JCP.0b013e318166c4d5.

Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review

Keming Gao  1 , David E Kemp, Stephen J Ganocy, Prashant Gajwani, Guohua Xia, Joseph R Calabrese
Affiliations

Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review

Keming Gao et al. J Clin Psychopharmacol. 2008 Apr.

Abstract

Objectives: Newer atypical antipsychotics have been reported to cause a lower incidence of extrapyramidal side effects (EPS) than conventional agents. This review is to compare antipsychotic-induced EPS relative to placebo in bipolar disorder (BPD) and schizophrenia.

Methods: English-language literature cited in Medline was searched with terms antipsychotics, placebo-controlled trial, and bipolar disorder or schizophrenia and then with antipsychotic (generic/brand name), safety, akathisia, EPS, or anticholinergic use, bipolar mania/depression, BPD, or schizophrenia, and randomized clinical trial. Randomized, double-blind, placebo-controlled, monotherapy studies with comparable doses in both BPD and schizophrenia were included. Absolute risk increase and number needed to treat to harm (NNTH) for akathisia, overall EPS, and anticholinergic use relative to placebo were estimated.

Results: Eleven trials in mania, 4 in bipolar depression, and 8 in schizophrenia were included. Haloperidol significantly increased the risk for akathisia, overall EPS, and anticholinergic use in both mania and schizophrenia, with a larger magnitude in mania, an NNTH for akathisia of 4 versus 7, EPS of 3 versus 5, and anticholinergic use of 2 versus 4, respectively Among atypical antipsychotics, only ziprasidone significantly increased the risk for overall EPS and anticholinergic use in both mania and schizophrenia, again with larger differences in mania, an NNTH for overall EPS of 11 versus 19, and anticholinergic use of 5 versus 9. In addition, risks were significantly increased for overall EPS (NNTH = 5) and anticholinergic use (NNTH = 5) in risperidone-treated mania, akathisia in aripiprazole-treated mania (NNTH = 9) and bipolar depression (NNTH = 5), and overall EPS (NNTH = 19) in quetiapine-treated bipolar depression.

Conclusions: Bipolar patients, especially in depression, were more vulnerable to having acute antipsychotic-induced movement disorders than those with schizophrenia.

PubMed Disclaimer

References

    1. Hunt N, Silverstone T. Tardive dyskinesia in bipolar affective disorder: a catchment care study. Int Clin Psychopharmacol. 1991;6:45–50. - PubMed
    1. Hamra BJ, Nasrallah HA, Clancy J, et al. Psychiatric diagnosis and risk for tardive dyskinesia. Arch Gen Psychiatry. 1983;40:346–347. - PubMed
    1. Nasrallah HA, Churchill CM, Hamdan-Allan GA. Higher frequency of neuroleptic-induced dsytonia in mania than in schizophrenia. Am J Psychiatry. 1988;145:1455–1456. - PubMed
    1. Kane JM. Tardive dyskinesia in affective disorders. J Clin Psychiatry. 1999;60(suppl 5):43–47. - PubMed
    1. Khanna R, Das A, Damodaran SS. Prospective study of neuroleptic-induced dystonia in mania and schizophrenia. Am J Psychiatry. 1992;149:511–513. - PubMed

Publication types

MeSH terms

Substances